VEA
DNLI icon

Virtus ETF Advisers’s Denali Therapeutics DNLI Stock Holding History

Virtus ETF Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,029
Closed -$61.7K – 527
2024
Q4 		$61.7K Sell
3,029
-1,135
-27% -$29.1K 0.03% 440
2024
Q3 		$121K Buy
4,164
+72
+2% +$1.78K 0.06% 351
2024
Q2 		$95K Buy
4,092
+357
+10% +$6.85K 0.05% 336
2024
Q1 		$76.6K Sell
3,735
-259
-6% -$4.87K 0.04% 398
2023
Q4 		$85.7K Buy
3,994
+949
+31% +$18.8K 0.05% 414
2023
Q3 		$62.8K Sell
3,045
-304
-9% -$7.71K 0.04% 401
2023
Q2 		$98.8K Buy
3,349
+56
+2% +$1.57K 0.06% 388
2023
Q1 		$75.9K Sell
3,293
-1,259
-28% -$34.6K 0.04% 392
2022
Q4 		$127K Sell
4,552
-323
-7% -$9.61K 0.07% 400
2022
Q3 		$150K Buy
4,875
+36
+0.7% +$1.17K 0.06% 354
2022
Q2 		$142K Buy
4,839
+1,406
+41% +$36.8K 0.05% 326
2022
Q1 		$110K Sell
3,433
-200
-6% -$6.88K 0.05% 287
2021
Q4 		$162K Buy
3,633
+803
+28% +$38K 0.06% 320
2021
Q3 		$143K Sell
2,830
-150
-5% -$8.45K 0.06% 349
2021
Q2 		$234K Sell
2,980
-664
-18% -$41.1K 0.1% 231
2021
Q1 		$208K Buy
3,644
+58
+2% +$3.88K 0.09% 322
2020
Q4 		$300K Sell
3,586
-8,878
-71% -$537K 0.12% 211
2020
Q3 		$447K Sell
12,464
-1,710
-12% -$51.5K 0.23% 147
2020
Q2 		$343K Sell
14,174
-4,846
-25% -$114K 0.16% 272
2020
Q1 		$333K Sell
19,020
-2,785
-13% -$58.1K 0.14% 216
2019
Q4 		$380K Buy
21,805
+8,311
+62% +$138K 0.06% 275
2019
Q3 		$207K Sell
13,494
-752
-5% -$14.4K 0.04% 242
2019
Q2 		$296K Buy
14,246
+1,045
+8% +$23.4K 0.06% 223
2019
Q1 		$307K Sell
13,201
-1,589
-11% -$33.2K 0.65% 59
2018
Q4 		$306K Sell
14,790
-10,928
-42% -$198K 0.05% 107
2018
Q3 		$559K Sell
25,718
-18,899
-42% -$313K 0.06% 110
2018
Q2 		$680K Buy
+44,617
New +$841K 0.6% 107

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Virtus ETF Advisers's DNLI Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 3,029 shares — an estimated $61.7K sold.

Virtus ETF Advisers first reported a position in DNLI in Q2 2018 and held it in 27 quarters. The position peaked at $680K in Q2 2018. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,029 Denali Therapeutics shares in Q1 2025, an estimated $61.7K.
  • Virtus ETF Advisers first reported a position in Denali Therapeutics in Q2 2018 and held it in 27 quarters.
  • Virtus ETF Advisers's Denali Therapeutics position peaked at $680K in Q2 2018.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.